What does 'solid phase' actually mean in solid-phase peptide synthesis?

It refers to the insoluble resin support to which the growing peptide chain is anchored throughout the synthesis. Because the peptide is attached to a solid bead, excess reagents and byproducts can simply be washed away after each reaction step — you never lose your product in a filtration step the way you would in solution-phase chemistry.

What's the difference between Boc and Fmoc chemistry in SPPS?

Both are protecting-group strategies for the alpha-amine of each incoming amino acid. Boc (tert-butyloxycarbonyl) chemistry uses strong acid (TFA) for deprotection at each step and hydrofluoric acid for final cleavage — effective but hazardous. Fmoc (9-fluorenylmethyloxycarbonyl) chemistry uses mild base (piperidine) for deprotection and is now the dominant approach in most research and pharmaceutical settings because it's more compatible with sensitive side-chain protecting groups and doesn't require HF handling.

How pure does a synthesised peptide need to be for research use?

It depends on the application, but analytical-grade research peptides are typically characterised to ≥95% purity by HPLC, with identity confirmed by mass spectrometry. For pharmaceutical manufacturing, specifications are considerably stricter and defined by regulatory guidelines. A peptide with unlisted impurities or truncated sequences can produce misleading results in biological assays, which is why purity documentation is essential.

Are synthesised peptides legal to purchase in Australia?

This depends entirely on the specific peptide and its intended use. Peptides intended for human therapeutic use must be registered or listed on the ARTG, or accessed through the TGA's Special Access Scheme or Authorised Prescriber pathway. Many synthesised peptides marketed online in Australia — particularly those promoted for body composition or performance — are unapproved therapeutic goods, and supplying them without TGA approval is unlawful. The TGA has issued public warnings and taken enforcement action in this area.

Why can't most peptides simply be taken orally?

Most peptides are broken down rapidly in the gastrointestinal tract by digestive enzymes (proteases and peptidases), and even fragments that survive enzymatic degradation face poor permeability across the intestinal wall. This is why many peptide-based drugs are administered by injection rather than orally. Oral peptide delivery remains an active area of pharmaceutical research, with strategies including enzyme-resistant D-amino acid substitutions, encapsulation technologies, and permeation enhancers — but it's genuinely hard chemistry.

Solid-Phase Peptide Synthesis

By Priya Nandakumar · 26 June 2026 · 7 min read

Abstract composition with white cubes, pink ribbon, and scattered particles.

Building molecules from scratch, one bond at a time

There are roughly 7,000 peptide bonds formed every second inside a single human cell. Ribosomes handle that at a pace no chemist could touch. But when researchers need a specific sequence , one that doesn't exist in nature, or exists in vanishingly small amounts , they can't just ask a ribosome nicely. They reach for solid-phase peptide synthesis instead.

SPPS, as it's almost universally abbreviated, is the workhorse technique that turned peptide chemistry from a slow, painstaking craft into something close to routine. Understanding how it works illuminates a lot about why certain peptides are structurally possible, why purity matters so enormously, and why regulatory frameworks around synthesised peptides are as strict as they are in Australia.

The problem SPPS was designed to solve

Before 1963, building a peptide chain in solution was a nightmare. Every coupling step produced a mixture of products. You'd synthesise a few amino acids into a chain, then spend longer purifying it than you did making it. Yields dropped with each added residue. Anything longer than five or six amino acids was practically heroic to produce cleanly.

Robert Bruce Merrifield's insight , published in the Journal of the American Chemical Society in 1963; was conceptually elegant. Anchor the growing peptide chain to an insoluble solid support (a resin bead), add amino acids sequentially, and wash away all the reagents and byproducts between each step without ever losing your chain. When you're done, cleave the finished peptide off the resin. Merrifield won the Nobel Prize in Chemistry in 1984 for it, which, honestly, feels well earned.

The chemistry, step by step

Each synthesis cycle follows the same four-step logic, repeated for every residue you want to add.

1. Resin loading. The first amino acid, always the C-terminal residue of the target sequence, is attached to a cross-linked polystyrene or polyethylene glycol resin through its carboxyl group. The resin bead is effectively the scaffold everything else gets built on.

2. Deprotection. Amino acids arrive at the reaction with their alpha-amine group temporarily blocked by a protecting group. The two dominant chemistries used today are Boc (tert-butyloxycarbonyl) and Fmoc (9-fluorenylmethyloxycarbonyl). Fmoc is now more common in research settings because it uses milder conditions and is compatible with a wider range of side-chain protecting groups. Deprotection; removing that Fmoc group with piperidine, typically, exposes the free amine ready for the next coupling.

3. Coupling. The next protected amino acid is activated, usually with reagents like HBTU, HATU, or DIC/HOBt; and reacts with the free amine to form a new peptide bond. This step is where a lot of the quality control focus sits. Incomplete coupling means a fraction of chains are truncated, which causes headaches at purification.

4. Wash. All unreacted reagents, activating agents, and byproducts are flushed through the resin with solvent. This is the whole point of doing chemistry on a solid support, the product stays put while everything unwanted goes down the drain.

Repeat deprotection and coupling for every residue. At the end, a cleavage cocktail, typically trifluoroacetic acid with scavengers to mop up reactive carbocations; removes the peptide from the resin and strips the remaining side-chain protecting groups simultaneously.

Why purity is non-negotiable

A 99% coupling efficiency sounds excellent. But run that across a 30-residue peptide and 0.99^30 gives you roughly 74% full-length product at best, before any other side reactions. The rest is a soup of deletion sequences, truncated chains, and racemised residues. That's why high-performance liquid chromatography (HPLC) purification follows every synthesis, and why mass spectrometry confirmation of the final sequence is standard. A peptide that's 85% pure is a different thing chemically to one that's 99.5% pure, and in research or pharmaceutical contexts, that difference is the whole ballgame.

This is worth keeping in mind when you see claims about synthesised peptides in the Australian marketplace. The TGA's position is clear: peptides that are not listed or registered on the Australian Register of Therapeutic Goods (ARTG) and are being supplied for human use are, in most cases, being supplied unlawfully. Purity documentation, Good Manufacturing Practice certification, and regulatory approval aren't optional extras, they are the minimum bar. The TGA has been actively enforcing this, particularly around peptides marketed for performance or body composition purposes, which frequently lack that approval.

I'll be direct: the number of products in that space that have any genuine quality documentation is, in my view, far smaller than the marketing would suggest. That's not a popular thing to say, but the chemistry backs it up.

Automated synthesis and modern scale

Merrifield built his first synthesiser by hand, out of a modified lab setup on his bench. Today, automated peptide synthesisers can run overnight cycles unattended, with software-controlled coupling and deprotection steps and real-time monitoring of reaction completeness via UV absorbance of the Fmoc chromophore. Microwave-assisted SPPS has also shortened coupling times from hours to minutes for difficult sequences.

Scale varies enormously; from milligrams for a novel research sequence to kilograms for a pharmaceutical active ingredient. The GLP-1 receptor agonist class of peptides, for instance, are manufactured at commercial scale using SPPS-derived processes, though the final production routes for approved drugs often involve hybrid chemical-enzymatic approaches for efficiency.

I was reading about this during a long run along the Cooks River last weekend, podcast in one ear (currently: Bear Brook, if anyone wants a recommendation) and thinking about how much invisible chemistry goes into a single vial of anything. The gap between "a peptide sequence exists" and "a pharmaceutically useful product exists" is enormous, and SPPS is just the first leap across that gap.

SPPS and pharmacokinetic design

One reason SPPS matters to pharmacokinetics is that it allows systematic structural modification. Researchers can substitute individual residues, flip stereocentres from L- to D-amino acids to resist proteolytic degradation, add fatty acid chains to extend half-life, or cyclise sequences to constrain conformation. None of that is possible with extraction from biological sources.

These modifications directly affect how a peptide behaves after administration. D-amino acid substitutions, for instance, are known to slow breakdown by endogenous peptidases, which matters enormously for anything delivered via subcutaneous injection, where the peptide needs to survive long enough to reach systemic circulation. Similarly, understanding first-pass dynamics is less relevant for injectable peptides than for oral ones, since most peptides are extensively degraded in the gastrointestinal tract. The first-pass metabolism picture for oral peptide delivery remains one of the genuinely hard problems in the field.

Where the regulatory lines sit in Australia

For completeness: peptides synthesised for legitimate pharmaceutical development in Australia must comply with TGA manufacturing requirements, including GMP. Any peptide intended for human therapeutic use must either hold ARTG registration/listing, be accessed through the Special Access Scheme, or be prescribed under the Authorised Prescriber pathway. Peptides that are prescription-only fall under Schedule 4 of the Poisons Standard at minimum; some, depending on their pharmacological profile, may attract higher scheduling.

The biochemistry of SPPS is genuinely fascinating on its own terms; it doesn't need to be dressed up in aspirational language about performance or longevity. The science stands up without the hype, and the hype tends to obscure the parts that actually matter, like purity, characterisation, and regulatory status.

Sources

, Priya Nandakumar, Pharmacology writer, peptides & PK

Common questions

What does 'solid phase' actually mean in solid-phase peptide synthesis?: It refers to the insoluble resin support to which the growing peptide chain is anchored throughout the synthesis. Because the peptide is attached to a solid bead, excess reagents and byproducts can simply be washed away after each reaction step — you never lose your product in a filtration step the way you would in solution-phase chemistry.
What's the difference between Boc and Fmoc chemistry in SPPS?: Both are protecting-group strategies for the alpha-amine of each incoming amino acid. Boc (tert-butyloxycarbonyl) chemistry uses strong acid (TFA) for deprotection at each step and hydrofluoric acid for final cleavage — effective but hazardous. Fmoc (9-fluorenylmethyloxycarbonyl) chemistry uses mild base (piperidine) for deprotection and is now the dominant approach in most research and pharmaceutical settings because it's more compatible with sensitive side-chain protecting groups and doesn't require HF handling.
How pure does a synthesised peptide need to be for research use?: It depends on the application, but analytical-grade research peptides are typically characterised to ≥95% purity by HPLC, with identity confirmed by mass spectrometry. For pharmaceutical manufacturing, specifications are considerably stricter and defined by regulatory guidelines. A peptide with unlisted impurities or truncated sequences can produce misleading results in biological assays, which is why purity documentation is essential.
Are synthesised peptides legal to purchase in Australia?: This depends entirely on the specific peptide and its intended use. Peptides intended for human therapeutic use must be registered or listed on the ARTG, or accessed through the TGA's Special Access Scheme or Authorised Prescriber pathway. Many synthesised peptides marketed online in Australia — particularly those promoted for body composition or performance — are unapproved therapeutic goods, and supplying them without TGA approval is unlawful. The TGA has issued public warnings and taken enforcement action in this area.
Why can't most peptides simply be taken orally?: Most peptides are broken down rapidly in the gastrointestinal tract by digestive enzymes (proteases and peptidases), and even fragments that survive enzymatic degradation face poor permeability across the intestinal wall. This is why many peptide-based drugs are administered by injection rather than orally. Oral peptide delivery remains an active area of pharmaceutical research, with strategies including enzyme-resistant D-amino acid substitutions, encapsulation technologies, and permeation enhancers — but it's genuinely hard chemistry.